Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIG1 | P18858 | 1/20 | 0.66 |
| ▸ | DAO | P14920 | 2/20 | 0.53 |
| ▸ | PTPRC | P08575 | 1/20 | 0.51 |
| ▸ | CES1 | P23141 | 2/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31310235 | 0.80 | LIG1 (1.00) | LIG1DAOCES1NSD2BCHE | |
| SCHEMBL1742133 | 0.80 | LIG1 (1.00) | LIG1DAOCES1NSD2BCHE | |
| SCHEMBL2921667 | 0.79 | CES1 (0.53) | LIG1DAOPTPRCCES1L3MBTL1 | |
| SCHEMBL26403502 | 0.78 | LIG1 (0.72) | LIG1DAOCES1NSD2BCHE | |
| SCHEMBL2424940 | 0.75 | KDM4E (0.54) | PTPRCL3MBTL1ROCK2CSF1RKDR | |
| SCHEMBL3737913 | 0.74 | GSK3B (0.49) | PTPRCCES1ALOX5ROCK2CSF1R | |
| SCHEMBL69292 | 0.74 | MAPT (0.61) | PTPRCL3MBTL1MAPTMEN1KMT2A | |
| SCHEMBL10648376 | 0.74 | LIG1 (0.49) | LIG1DAOCES1NSD2BCHE | |
| SCHEMBL6692699 | 0.73 | LRRK2 (0.49) | GSK3B | |
| SCHEMBL5323040 | 0.73 | L3MBTL1 (0.65) | LIG1DAOCES1NSD2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160106711-A1 | 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-21 | — | — | US | disclosed |
| US-20160106711-A1 | 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-21 | — | — | US | disclosed |
| US-20160106711-A1 | 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-21 | — | — | US | disclosed |
| EP-2320906-B1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | BETA PHARMA CANADA INC (CA) | 2016-02-24 | — | — | EP | disclosed |
| WO-2014047437-A1 | 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-03-27 | — | — | WO | disclosed |
| WO-2014047437-A1 | 3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-03-27 | — | — | WO | disclosed |
| US-8404736-B2 | Heterocyclic amide derivatives as EP4 receptor antagonists | BETA PHARMA CANADA INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-8404736-B2 | Heterocyclic amide derivatives as EP4 receptor antagonists | BETA PHARMA CANADA INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | BETA PHARMA CANADA INC. (CA) | 2011-06-09 | — | — | US | disclosed |
| EP-1335901-B1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | MERCK SERONO SA (CH) | 2010-04-14 | — | — | EP | disclosed |
| WO-2010019796-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS | CHEMIETEK, LLC (US) | 2010-02-18 | — | — | WO | disclosed |
| US-7312358-B2 | Pharmaceutically active sulfanilide derivatives | LABORATOIRES SERONO SA (CH) | 2007-12-25 | — | — | US | disclosed |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | MERCK SERONO SA (CH) | 2004-04-15 | — | — | US | disclosed |
| EP-1335901-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002032864-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-25 | — | — | WO | disclosed |
| EP-0341990-B1 | Cephalosporins, process for their preparation and pharmaceutical compositions | ICI PLC (GB) | 1994-11-09 | — | — | EP | disclosed |
| US-5008259-A | Antibiotics active against strains of Pseudomonas and stable to beta-lactamase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-04-16 | — | — | US | disclosed |
| EP-0341990-A2 | Cephalosporins, process for their preparation and pharmaceutical compositions | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-11-15 | — | — | EP | disclosed |
| US-4780477-A | Isatin compositions having anti-ulcer activities | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 1988-10-25 | — | — | US | disclosed |
| EP-0205299-A2 | Isatin derivatives, compositions containing the same, and the use thereof for ulcer diseases | Kissei Pharmaceutical Co. Ltd. (JP) | 1986-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106711-A1 | 3-3-Di-Substituted-Oxindoles as Inhibitors of Translation Initiation | RIOX2, EIF4A3, RPL35 | LIG1 1491/4885DAO 364/4885PTPRC 2194/4885 |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | OXTR, AVPR2, OPRL1 | LIG1 4488/4885DAO 1849/4885PTPRC 3329/4885 |
| US-20110136887-A1 | Heterocyclic Amide Derivatives as EP4 Receptor Antagonists | PTGER4, PTGER1, PTGER2 | LIG1 4820/4885DAO 3448/4885PTPRC 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.